Bloodless Diagnostics Inc. — SEC Form D Filing

Bloodless Diagnostics Inc. filed an SEC Form D on November 10, 2026, reporting $1.27M raised in Medical Diagnostics.

Form D filing details

Filing
SEC Form D
Filing date
November 10, 2026
Amount reported
$1.27M
Round stage
Seed
Industry
Medical Diagnostics
Website
https://bloodlessdx.com/

What the company does

Securities: Simple Agreement for Future Equity. Exemption: Rule 506(b). Incorporated: NORTH CAROLINA

Problem

Conventional diagnostic tests require drawing blood or collecting other bodily fluids, processing specimens, and often relying on laboratory infrastructure, while only providing a single snapshot rather than continuous exposure monitoring.

Solution

Bloodless Diagnostics is developing a skin-applied diagnostic platform that uses engineered affinity reagents to detect target molecules in interstitial fluid, triggering a localized, visible immune reaction on the skin without requiring sample collection or instruments.

Why now

Rising demand for decentralized point-of-care testing and continuous outbreak surveillance has created an urgency for non-invasive, lab-free diagnostic tools.

Verdict

This cleared because investors bought into the operational simplicity of an instrument-free, skin-reactive readout, not because they believed in the maturity of the commercial pathway. Underwriting a modest $1.28M check was a bet that sidestepping microfluidics, digital readers, and sample transport would unlock friction-free adoption. However, upside remained structurally capped by the absence of an identifiable budget owner and the obvious regulatory friction inherent in deliberately triggering localized immune reactions on human skin to generate a diagnostic signal.

Source: SEC EDGAR Form D filing